Topic: Advance in Immunotherapy for Genito-urinary Cancers

Genitourinary cancers include prostate cancer, urothelial cancer, renal cancer, testicular cancer, and penile cancer, and are notably prevalent, especially in men. Testicular cancer, regardless of the stage at diagnosis, is largely curable with chemotherapy. For the other forms, a majority of patients with non-metastatic disease can achieve a cure through radical surgery or radiotherapy. Nevertheless, it is not uncommon for metastatic disease to be present at initial diagnosis, and a significant proportion of patients initially diagnosed with organ-confined disease will later develop metastatic disease. Unfortunately, the prognosis in cases of metastases has traditionally been poor, with the majority of patients succumbing to their condition. The introduction of modern immunotherapy, using anti-PD1 and anti-PDL1 agents, has revolutionized the treatment paradigm, especially in urothelial and kidney cancer, with significant prolongation of survival. This Special Issue of the Journal of Cancer Metastasis and Treatment aims to provide a comprehensive review of the stage-of-the-art and the most recent developments in immunotherapy for genitourinary cancers.

We welcome submissions in the following areas:
● The role of immunotherapy in non-muscle invasive bladder cancer;
● The role of immunotherapy in non-metastatic, muscle-invasive bladder cancer;
● The role of immunotherapy in metastatic urothelial cancer;
● The role of surgery in metastatic renal cancer in the era of modern immunotherapy;
● Radiotherapy and immunotherapy in bladder cancer;
● The role of immunotherapy in non-metastatic renal cancer;
● The role of immunotherapy in metastatic renal cancer;
● The role of immunotherapy in non-clear-cell renal cancer;
● Biomarkers and prognostic models in patients with genitourinary cancers treated with immunotherapy.

Urothelial cancer, renal cancer, immunotherapy, prostate cancer, genitourinary cancer

20 Aug 2024